$Presence of multiple recurrent mutations confers poor trial outcome of relapsed/refractory CLL.$

Presence of multiple recurrent mutations confers poor trial outcome of relapsed/refractory CLL.

Although TP53, NOTCH1, and SF3B1 mutations may impair prognosis of patients with chronic lymphocytic leukemia (CLL) receiving frontline therapy, the impact of these mutations or any other, alone or in combination, remains unclear at relapse. The genome of 114 relapsed/refractory patients included in...

Volledige beschrijving

Bibliografische gegevens
Hoofdauteurs:	Guièze, R, Robbe, P, Clifford, R, de Guibert, S, Pereira, B, Timbs, A, Dilhuydy, M, Cabes, M, Ysebaert, L, Burns, A, Nguyen-Khac, F, Davi, F, Véronèse, L, Combes, P, Le Garff-Tavernier, M, Leblond, V, Merle-Béral, H, Alsolami, R, Hamblin, A, Mason, J, Pettitt, A, Hillmen, P, Taylor, J, Knight, S, Tournilhac, O, Schuh, A
Formaat:	Journal article
Taal:	English
Gepubliceerd in:	American Society of Hematology 2015

Presence of multiple recurrent mutations confers poor trial outcome of relapsed/refractory CLL.

Gelijkaardige items